R 115866 Property

Boiling point:

561.0±60.0 °C(Predicted)

Density 

1.26±0.1 g/cm3(Predicted)

storage temp. 

Keep in dark place,Sealed in dry,Store in freezer, under -20°C

solubility 

Soluble in DMSO

form 

Powder

pka

2.70±0.10(Predicted)

color 

White to off-white

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

R 115866 Chemical Properties,Usage,Production

Uses

Talarozole is a retinoic acid metabolism blocking agent (RAMBA) that can be used for treating dermatalogical diseases such as psoriasis and acne.

Definition

ChEBI: N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine is a member of the class of benzothiazoles that is 2-amino-1,3-benzothiazole in which one of the amino hydrogens is replaced by a 4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl group. It is a member of triazoles, a member of benzothiazoles, an aromatic amine and a secondary amino compound.

Biological Activity

talarozole is a selective inhibitor of cytochrome p450 with an ic50 at 4 nm [1].cytochrome p450 is concerned with oxidative metabolism of many organic chemicals of diverse structure,both in exogenous and endogenous environment. cytochrome p450 are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act.talarozole is a potent and selective inhibitor of cytochrome p450 26-mediated breakdown of endogenous all-trans-retinoic acid for the treatment of psoriasis and acne. talarozole treatment increased the mrna expression of crabp2, krt4, cyp26a1 and cyp26b1 dose, meanwhile, compared with vehicle-treated skin, decreased the expression of krt2 and il-1α. there was no mrna change in retinol-metabolizing enzymes. no induction of epidermal thickness or overt skin inflammation in talarozole-treated skin. immunofluorescence analysis substantiated an upregulation of krt4 protein, however, there were no upregulation of cyp26b1 and cyp26a1 expression was found.[1, 2]there were 0.1% of the dose found in the skin itself after 12-24 h. the results of distribution of talarozole within the skin show that 80% was located in the epidermis, meanwhile, the remaining 20% was detected in the dermis. [3]

target

cytochrome P450

References

[1] pavez loriè e, cools m, borgers m, topical treatment with cyp26 inhibitor talarozole (r115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. the british journal of dermatology,2009,160(1):26-36.
[2] geria an, scheinfeld ns. talarozole, a selective inhibitor of p450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. current opinion in investigational drugs,2008 ,9(11):1228-1237.
[3] baert b, de spiegeleer b. local skin pharmacokinetics of talarozole, a new retinoic acid metabolism-blocking agent. skin pharmacol physiol,2011,24(3):151-159